Renata Past Earnings Performance
Past criteria checks 1/6
Renata's earnings have been declining at an average annual rate of -6.2%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 9.8% per year. Renata's return on equity is 7.1%, and it has net margins of 6.3%.
Key information
-6.2%
Earnings growth rate
-6.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | 9.8% |
| Return on equity | 7.1% |
| Net Margin | 6.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Renata makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 36,469 | 2,294 | 10,667 | 0 |
| 31 Dec 23 | 35,689 | 2,143 | 10,700 | 0 |
| 30 Sep 23 | 34,040 | 2,114 | 10,197 | 0 |
| 30 Jun 23 | 32,971 | 2,339 | 9,676 | 0 |
| 31 Mar 23 | 32,545 | 3,674 | 10,457 | 0 |
| 31 Dec 22 | 31,670 | 4,461 | 9,461 | 0 |
| 30 Sep 22 | 31,723 | 4,974 | 8,762 | 0 |
| 30 Jun 22 | 31,071 | 5,111 | 8,321 | 0 |
| 31 Mar 22 | 31,848 | 5,537 | 8,353 | 0 |
| 31 Dec 21 | 30,782 | 5,408 | 7,579 | 0 |
| 30 Sep 21 | 30,336 | 5,206 | 7,680 | 0 |
| 30 Jun 21 | 29,971 | 5,062 | 7,659 | 0 |
| 31 Mar 21 | 26,622 | 4,594 | 5,694 | 0 |
| 31 Dec 20 | 26,596 | 4,424 | 6,238 | 0 |
| 30 Sep 20 | 25,115 | 4,338 | 5,840 | 0 |
| 30 Jun 20 | 24,675 | 4,012 | 6,023 | 0 |
| 31 Mar 20 | 25,791 | 4,353 | 6,758 | 0 |
| 31 Dec 19 | 24,265 | 4,114 | 6,551 | 0 |
| 30 Sep 19 | 24,039 | 3,943 | 6,537 | 0 |
| 30 Jun 19 | 22,221 | 3,823 | 6,040 | 0 |
| 31 Mar 19 | 20,633 | 3,452 | 5,633 | 0 |
| 31 Dec 18 | 20,282 | 3,397 | 5,445 | 0 |
| 30 Sep 18 | 19,566 | 3,241 | 5,081 | 0 |
| 30 Jun 18 | 19,050 | 3,106 | 5,086 | 0 |
| 31 Mar 18 | 18,925 | 3,020 | 5,089 | 0 |
| 31 Dec 17 | 18,238 | 2,867 | 4,668 | 0 |
| 30 Sep 17 | 17,783 | 2,818 | 4,557 | 0 |
| 30 Jun 17 | 16,645 | 2,678 | 4,229 | 0 |
| 31 Mar 17 | 16,137 | 2,522 | 4,046 | 0 |
| 31 Dec 16 | 15,426 | 2,446 | 3,864 | 0 |
| 30 Sep 16 | 15,644 | 2,499 | 3,487 | 0 |
| 30 Jun 16 | 14,777 | 2,274 | 3,714 | 0 |
| 31 Mar 16 | 13,592 | 2,145 | 3,527 | 0 |
| 31 Dec 15 | 13,425 | 2,076 | 3,463 | 0 |
| 30 Sep 15 | 12,566 | 1,993 | 3,283 | 0 |
| 30 Jun 15 | 12,241 | 1,902 | 3,126 | 0 |
| 31 Mar 15 | 11,738 | 1,761 | 2,957 | 0 |
| 31 Dec 14 | 11,433 | 1,687 | 2,827 | 0 |
| 30 Sep 14 | 10,616 | 1,552 | 2,403 | 0 |
| 30 Jun 14 | 10,138 | 1,528 | 2,206 | 0 |
| 31 Mar 14 | 9,709 | 1,444 | 2,153 | 0 |
| 31 Dec 13 | 9,131 | 1,397 | 2,074 | 0 |
| 30 Sep 13 | 8,931 | 1,375 | 2,114 | 0 |
| 30 Jun 13 | 8,501 | 1,280 | 2,011 | 0 |
Quality Earnings: RENATA has high quality earnings.
Growing Profit Margin: RENATA's current net profit margins (6.3%) are lower than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RENATA's earnings have declined by 6.2% per year over the past 5 years.
Accelerating Growth: RENATA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: RENATA had negative earnings growth (-37.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.6%).
Return on Equity
High ROE: RENATA's Return on Equity (7.1%) is considered low.